• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis.

作者信息

Stratta R J, Alloway R R, Lo A, Hodge E

机构信息

Department of Surgery, University of Tennessee-Memphis, Memphis, Tennessee, USA.

出版信息

Transplant Proc. 2001 Feb-Mar;33(1-2):1692-3. doi: 10.1016/s0041-1345(00)02644-0.

DOI:10.1016/s0041-1345(00)02644-0
PMID:11267472
Abstract
摘要

相似文献

1
A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis.一项在同期肾胰腺移植中比较两种达利珠单抗给药策略与不进行抗体诱导的多中心试验：中期分析。
Transplant Proc. 2001 Feb-Mar;33(1-2):1692-3. doi: 10.1016/s0041-1345(00)02644-0.
2
A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.一项多中心、开放标签、比较两种达利珠单抗给药策略与不使用抗体诱导剂联合他克莫司、霉酚酸酯和类固醇预防同期肾胰腺移植受者急性排斥反应的试验：中期分析。
Clin Transplant. 2002 Feb;16(1):60-8. doi: 10.1034/j.1399-0012.2002.00108.x.
3
A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis.一项多中心、开放标签、比较两种达利珠单抗给药策略与同期肾胰腺移植中不进行抗体诱导的对照试验：6个月中期分析。
Transplant Proc. 2002 Aug;34(5):1903-5. doi: 10.1016/s0041-1345(02)03117-2.
4
Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
Transplant Proc. 2001 Feb-Mar;33(1-2):1701-3. doi: 10.1016/s0041-1345(00)02649-x.
5
Daclizumab as escape therapy for late acute kidney rejection in the presence of FK506 nephrotoxicity.在存在FK506肾毒性的情况下，使用达利珠单抗作为晚期急性肾移植排斥反应的挽救治疗。
Transpl Int. 2000;13(2):169-71. doi: 10.1007/s001470050317.
6
Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.两剂达利珠单抗方案用于同期肾胰腺移植受者：一项多中心随机研究的主要终点分析
Transplantation. 2003 Apr 27;75(8):1260-6. doi: 10.1097/01.TP.0000062838.38351.2A.
7
One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
Transplant Proc. 2004 May;36(4):1080-1. doi: 10.1016/j.transproceed.2004.04.067.
8
Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
Transplant Proc. 2002 Mar;34(2):551-2. doi: 10.1016/s0041-1345(01)02842-1.
9
Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.白细胞介素-2受体拮抗剂诱导联合他克莫司、霉酚酸酯和类固醇在同期肾胰腺移植中的初步临床经验。
Transpl Int. 2001 Dec;14(6):396-404. doi: 10.1007/s001470100005.
10
A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.一项前瞻性、随机、多中心研究，评估与在同期肾胰腺移植中不进行抗体诱导相比，两种剂量方案的达利珠单抗的安全性和有效性：3年结果。
Transplant Proc. 2005 Oct;37(8):3531-4. doi: 10.1016/j.transproceed.2005.09.058.